Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Rowe

Showing results (191-200 of 205) with videos related to

Pageof 21
Sort By:
Blood|January 28, 1999
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)R Advani, H I Saba, M S Tallman, et al.
Bone Marrow Transplantation|April 19, 2016
Autologous transplant remains the preferred therapy for relapsed APL in CR2C Ganzel, V Mathews, K Alimoghaddam, et al.
Advances in Experimental Medicine and Biology|September 29, 1999
Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)R Advani, G Visani, D Milligan, et al.
Journal of Research of the National Institute of Standards and Technology|August 9, 2016
Materials Research With Neutrons at NISTR L Cappelletti, C J Glinka, S Krueger, et al.
Bone Marrow Transplantation|May 22, 2024
Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trialsC Ganzel, Y Wang, K Roopcharan, et al.
Bone Marrow Transplantation|July 18, 2024
Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trialsC Ganzel, Y Wang, K Roopcharan, et al.
American Journal of Hematology|June 28, 2001
Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group StudyJ M Bennett, M S Young, J L Liesveld, et al.
Bone Marrow Transplantation|August 28, 1998
Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factorsJ E Lancet, A P Rapoport, R Brasacchio, et al.
Bone Marrow Transplantation|May 1, 1997
Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): long-term follow-up and analysis of prognostic factorsA P Rapoport, R Lifton, L S Constine, et al.
Leukemia|November 28, 2006
HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemiaA-L Herr, M Labopin, D Blaise, et al.
Pageof 21

Showing results (191-200 of 205) with videos related to

Sort By:
Pageof 21
Blood|January 28, 1999
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)R Advani, H I Saba, M S Tallman, et al.
Bone Marrow Transplantation|April 19, 2016
Autologous transplant remains the preferred therapy for relapsed APL in CR2C Ganzel, V Mathews, K Alimoghaddam, et al.
Advances in Experimental Medicine and Biology|September 29, 1999
Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)R Advani, G Visani, D Milligan, et al.
Journal of Research of the National Institute of Standards and Technology|August 9, 2016
Materials Research With Neutrons at NISTR L Cappelletti, C J Glinka, S Krueger, et al.
Bone Marrow Transplantation|May 22, 2024
Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trialsC Ganzel, Y Wang, K Roopcharan, et al.
Bone Marrow Transplantation|July 18, 2024
Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trialsC Ganzel, Y Wang, K Roopcharan, et al.
American Journal of Hematology|June 28, 2001
Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group StudyJ M Bennett, M S Young, J L Liesveld, et al.
Bone Marrow Transplantation|August 28, 1998
Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factorsJ E Lancet, A P Rapoport, R Brasacchio, et al.
Bone Marrow Transplantation|May 1, 1997
Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): long-term follow-up and analysis of prognostic factorsA P Rapoport, R Lifton, L S Constine, et al.
Leukemia|November 28, 2006
HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemiaA-L Herr, M Labopin, D Blaise, et al.
Pageof 21